Aprobado Zolgensma por la FDA. Su precio USD 2.1M

El pasado día 24 de mayo de 2019 aprobó la FDA la comercialización de ZOLGENSMA tal como parecía que iba a ser.
Copiamos de la web de la FDA:
STN: 125694
Proper Name: onasemnogene abeparvovec-xioi
Trade Name: ZOLGENSMA®
Manufacturer: AveXis, Inc 
Indication: For the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.
Product Information Package Insert-ZOLGENSMA
Supporting Documents May 24, 2019 Approval Letter - ZOLGENSMA

En la página web de Novartis habla del precio:
The current 10-year cost of chronic therapy, which is given over the patient's lifetime, can often exceed USD 4 million in just the first 10 years of a young child's life.[1] In addition, that therapy stops working if treatment is stopped.[2] Zolgensma is expected to save costs in the healthcare system compared to chronic treatment for the treatment and care of SMA.[3] The wholesale acquisition cost of Zolgensma of USD 2.125 million is:

•  50% of the 10-year cost of current chronic SMA treatment (estimated at USD 4.1 million)[1] 
• 50% below 10-year treatment costs for genetic pediatric ultra-rare diseases (estimated at USD 4.4 million to USD 5.7 million)[4]* 
• 50% below the ICER ultra-rare disease cost-effectiveness threshold; Zolgensma pricing places it at approximately USD 250,000 per quality-adjusted life-year (QALY)[5]

y de acuerdos con pagadores:

AveXis has partnered with Accredo® to offer a pay-over-time option of up to 5 years to help ease possible short-term budget constraints, especially for states, small payers and self-insured employers. In addition, CuraScript SD® has been selected as the sole specialty distributor given its rare disease experience, including gene and cell therapies.